{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:06:29Z","timestamp":1764327989281,"version":"3.46.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) is indicated for people with HIV who are virologically suppressed, including those with M184V\/I. Data on B\/F\/TAF effectiveness during viremia with M184V\/I are limited. This observational study retrospectively collected clinical\/demographic data from adults with viremia and M184V\/I receiving B\/F\/TAF or alternate antiretroviral therapy (ART). Virologic suppression at 3 and \u2265\u20096 months was evaluated. For participants with data, 5\/5 (100%) and 7\/8 (88%) on B\/F\/TAF and 4\/6 (67%) and 7\/10 (70%) on alternate ART achieved virologic suppression at 3 and \u2265\u20096 months, respectively. Virologic suppression was achieved in most people with HIV who were viremic with M184V\/I on B\/F\/TAF, as with alternate ART.<\/jats:p>","DOI":"10.1186\/s12981-025-00795-9","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:03:48Z","timestamp":1764327828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of B\/F\/TAF in adults with HIV who are viremic with M184V\/I"],"prefix":"10.1186","volume":"22","author":[{"given":"Charlotte-Paige","family":"Rolle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5395-7022","authenticated-orcid":false,"given":"Michelle L.","family":"D\u2019Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Corales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Schreibman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionne","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiu-Bin","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira","family":"Brar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"795_CR1","unstructured":"World Health Organization. HIV drug resistance. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance. Accessed 13 Jun 2025."},{"key":"795_CR2","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/infdis\/jit310","volume":"208","author":"KJ Metzner","year":"2013","unstructured":"Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis. 2013;208:1102\u201312.","journal-title":"J Infect Dis"},{"key":"795_CR3","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1093\/jac\/dkr291","volume":"66","author":"MA Wainberg","year":"2011","unstructured":"Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother. 2011;66:2346\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"795_CR4","doi-asserted-by":"publisher","first-page":"e0209605","DOI":"10.1371\/journal.pone.0209605","volume":"14","author":"P Machnowska","year":"2019","unstructured":"Machnowska P, Meixenberger K, Schmidt D, Jessen H, Hillenbrand H, Gunsenheimer-Bartmeyer B, et al. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 seroconverter study cohort. PLoS ONE. 2019;14:e0209605.","journal-title":"PLoS ONE"},{"key":"795_CR5","doi-asserted-by":"crossref","unstructured":"Kagan RM, Baxter JD, Kim T, Marlowe EM. HIV-1 drug resistance trends in the era of modern antiretrovirals: 2018\u20132024. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 9\u201312 Mar 2025; San Francisco, CA. Poster 730.","DOI":"10.1093\/ofid\/ofaf446"},{"key":"795_CR6","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.","journal-title":"EClinicalMedicine"},{"key":"795_CR7","doi-asserted-by":"publisher","first-page":"e41482","DOI":"10.1097\/MD.0000000000041482","volume":"104","author":"I Brar","year":"2025","unstructured":"Brar I, Ruane PJ, Berhe M, Brinson C, Benson P, Henry K, et al. Efficacy and safety of switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir\/abacavir\/lamivudine: results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study. Med (Baltim). 2025;104:e41482.","journal-title":"Med (Baltim)"},{"key":"795_CR8","doi-asserted-by":"publisher","first-page":"2456890","DOI":"10.1080\/25787489.2025.2456890","volume":"26","author":"B Trottier","year":"2025","unstructured":"Trottier B, Yang CJ, Watanabe D, Marchetti G, Elbirt D, De Barra E, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational bicstar cohort. HIV Res Clin Pract. 2025;26:2456890.","journal-title":"HIV Res Clin Pract"},{"key":"795_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","volume":"36","author":"PE Sax","year":"2022","unstructured":"Sax PE, Andreatta K, Molina JM, Daar ES, Hagins D, Acosta R, et al. High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I. AIDS. 2022;36:1511\u201320.","journal-title":"AIDS"},{"key":"795_CR10","unstructured":"Gilead Sciences, Inc. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Prescribing information. 2024. https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf. Accessed 13 Jun 2025."},{"key":"795_CR11","doi-asserted-by":"crossref","unstructured":"Chamberlain N, Mena L, Brock JB. BIC\/FTC\/TAF maintains viral suppression in patients with documented M184V\/I mutations: a real world experience. Presented at: IDWeek; 21\u201325 Oct 2020; Virtual. Poster 1003.","DOI":"10.1093\/ofid\/ofaa439.1189"},{"key":"795_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/QAI.0000000000002789","volume":"88","author":"C Orkin","year":"2021","unstructured":"Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, et al. Efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in females living with HIV: an integrated analysis of 5 trials. J Acquir Immune Defic Syndr. 2021;88:393\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"795_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","volume":"38","author":"C Orkin","year":"2024","unstructured":"Orkin C, Antinori A, Rockstroh JK, Moreno-Guillen S, Martorell CT, Molina JM, et al. Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy. AIDS. 2024;38:983\u201391.","journal-title":"AIDS"},{"key":"795_CR14","first-page":"559","volume":"30","author":"AM Wensing","year":"2022","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard HF, Paredes R, et al. 2022 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2022;30:559\u201374.","journal-title":"Top Antivir Med"},{"key":"795_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385:330\u201341.","journal-title":"N Engl J Med"},{"key":"795_CR16","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60:7086\u201397.","journal-title":"Antimicrob Agents Chemother"},{"key":"795_CR17","doi-asserted-by":"publisher","first-page":"e02406","DOI":"10.1128\/AAC.02406-20","volume":"65","author":"KL White","year":"2021","unstructured":"White KL, Osman N, Cuadra-Foy E, Brenner BG, Shivakumar D, Campigotto F, et al. Long dissociation of bictegravir from HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2021;65:e02406\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"795_CR18","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","volume":"4","author":"L Ciaffi","year":"2017","unstructured":"Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017;4:e384\u201392.","journal-title":"Lancet HIV"},{"key":"795_CR19","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1002\/j.1460-2075.1996.tb00777.x","volume":"15","author":"NKT Back","year":"1996","unstructured":"Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BO, van Kuilenburg ABP, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 1996;15:4040\u201349.","journal-title":"EMBO J"},{"key":"795_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/135965350601100302","volume":"11","author":"K Borroto-Esoda","year":"2006","unstructured":"Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377\u201384.","journal-title":"Antivir Ther"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00795-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:03:50Z","timestamp":1764327830000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00795-9","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by local institutional review boards. The study was conducted in accordance with the European Medicines Agency \u2013 Guideline on Good Pharmacovigilance Practices Module VIII \u2013 Post-Authorization Safety Studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C-PR reports research grants paid to their institution from Gilead Sciences, Inc., MSD, and ViiV Healthcare, payment or honoraria for speakers bureaus from Gilead Sciences, Inc. and ViiV Healthcare, and participation on an advisory board for ViiV Healthcare. DB reports payment or honoraria for speakers bureaus and support for attending speakers training\/bureau from Gilead Sciences, Inc. IB reports grants or contracts from Gilead Sciences, Inc., Merck, and ViiV Healthcare, consulting fees for advisory boards from Gilead Sciences, Inc., and support for attending speakers bureau training and payment or honoraria for speakers bureaus from Gilead Sciences, Inc. and ViiV Healthcare. MLD, RC, AM, and JG are employees and shareholders of Gilead Sciences, Inc. TS and C-BH declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}